TP53 and melanoma: Activation of the G2/M cell cycle checkpoint was found to induce cell cycle arrest and protection from cell death by granzyme B and TNFα exposure, which was reversed with Wee1 kinase inhibitor AZD1775, leading to enhanced CTL killing of antigen-positive tumor cells and in bystander antigen-negative tumor cells of oral cavity carcinoma, melanoma and colon adenocarcinoma harboring variable Tp53 genomic alterations (19).